Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.

BEAM

Beam Therapeutics (BEAM)

Beam Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:BEAM
DateTimeSourceHeadlineSymbolCompany
13/01/202523:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
13/01/202523:00GlobeNewswire Inc.Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated CatalystsNASDAQ:BEAMBeam Therapeutics Inc
07/01/202509:49Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
07/01/202509:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
03/01/202512:04Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202411:29Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
31/12/202411:26Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
20/12/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
20/12/202408:05Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
17/12/202423:00GlobeNewswire Inc.Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
09/12/202423:01Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
09/12/202405:45GlobeNewswire Inc.Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-conceptĀ for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
08/12/202403:30GlobeNewswire Inc.Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/12/202423:06Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
06/12/202423:00GlobeNewswire Inc.Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial OfficerNASDAQ:BEAMBeam Therapeutics Inc
04/12/202423:08Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
04/12/202423:00GlobeNewswire Inc.Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial LeaderNASDAQ:BEAMBeam Therapeutics Inc
13/11/202408:01GlobeNewswire Inc.Beam Therapeutics to Participate in 2024 Jefferies London Healthcare ConferenceNASDAQ:BEAMBeam Therapeutics Inc
09/11/202408:10Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
06/11/202401:06Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BEAMBeam Therapeutics Inc
06/11/202401:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
06/11/202401:00GlobeNewswire Inc.Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
06/11/202400:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202423:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BEAMBeam Therapeutics Inc
05/11/202422:30GlobeNewswire Inc.Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority ProgramsNASDAQ:BEAMBeam Therapeutics Inc
29/10/202421:30GlobeNewswire Inc.Beam Therapeutics to Hold Conference Call to Discuss Third Quarter 2024 Financial Results and Abstracts Accepted for Presentation at ASH Annual MeetingNASDAQ:BEAMBeam Therapeutics Inc
22/10/202407:11Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:BEAMBeam Therapeutics Inc
17/10/202407:44Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BEAMBeam Therapeutics Inc
16/10/202402:37Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
08/10/202408:00Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BEAMBeam Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:BEAM

Your Recent History

Delayed Upgrade Clock